| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/20/2004 | US20040097436 Administering to the mammal an effective antibacterial amount of a triterpene compound |
| 05/20/2004 | US20040097435 Method of treating parasitic infection |
| 05/20/2004 | US20040097434 For therapy of inflammatory diseases and conditions in humans and animals |
| 05/20/2004 | US20040097433 Reducing c-reactive protein; antiarthritic agents; adult respiratory system disorders; sepsis; Alzheimer's disease; antidiabetic agents |
| 05/20/2004 | US20040097432 Method of reducing cholesterol |
| 05/20/2004 | US20040097430 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| 05/20/2004 | US20040097429 Method for the reduction of the mammalian appetite |
| 05/20/2004 | US20040097428 Methods for inhibiting cancer and scar formation |
| 05/20/2004 | US20040097427 Fatty acid polyol polyester; veterinary medicine |
| 05/20/2004 | US20040097426 Prevent muscle degradation; arginine-glutamine dipeptide |
| 05/20/2004 | US20040097425 Peptide compounds |
| 05/20/2004 | US20040097424 Antilipemic agents; anticholesterol agents; cardiovascular disorders; antidiabetic agents |
| 05/20/2004 | US20040097422 Methods of use for tripeptidyl peptidase II inhibitors as anticancer agents |
| 05/20/2004 | US20040097420 Proteasome regulation of NF-kB activity |
| 05/20/2004 | US20040097416 Analgesics; neuropathic pain; bipolar disorders |
| 05/20/2004 | US20040097408 Anticancer agents |
| 05/20/2004 | US20040097407 Method for the synthesis of compounds of formula I and their uses thereof |
| 05/20/2004 | US20040097406 Pharmaceutical compositions and treatment methods - 4 |
| 05/20/2004 | US20040097405 Method of treating cartilage damage |
| 05/20/2004 | US20040097404 Supplement to be enternally administered for parenteral nutrition or partial enteral/oral nurtrition of the critically ill, the chronically ill and people with malnutrition |
| 05/20/2004 | US20040097403 Linkable sialyl lewis x analogs |
| 05/20/2004 | US20040097402 Therapy for infections; bactericides; synergistic mixtures |
| 05/20/2004 | US20040097401 Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions |
| 05/20/2004 | US20040097399 Medicinal association of a biguanine and a carrier, for example metformin and arginine |
| 05/20/2004 | US20040096939 Modifier of organelle metabolism |
| 05/20/2004 | US20040096925 Identifying enzyme inhibitors for treatment of skin, allergic and inflammatory disorders; cosmetics |
| 05/20/2004 | US20040096889 Compositions, organisms and methodologies employing a novel human kinase |
| 05/20/2004 | US20040096882 For injectable solutions; MRNA translation/degradation control |
| 05/20/2004 | US20040096881 For prophylactics/diagnostics/therapeutics; endothelial nitric oxide synthase (eNOS) |
| 05/20/2004 | US20040096877 For diagnosis/treatment/prevention of inflammation/asthma/ allergies |
| 05/20/2004 | US20040096865 For diagnosis/preventing/treating central nervous system disorders/obesity/diabetes; cell-free; solid phase synthesis; kits |
| 05/20/2004 | US20040096848 Oligomeric compounds for the modulation HIF-1alpha expression |
| 05/20/2004 | US20040096843 Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
| 05/20/2004 | US20040096566 Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof |
| 05/20/2004 | US20040096524 Cyclooxygenase-2 inhibitory withanolide compositions and method |
| 05/20/2004 | US20040096523 Reduces ability of mammal's leukocytes or platelets to become activated; administering potentiating compound; preventing nonpulmonary ischemia- reperfusion injury |
| 05/20/2004 | US20040096522 Synergistic mixtures |
| 05/20/2004 | US20040096521 Topical applying aspirin solutions |
| 05/20/2004 | US20040096519 Skin disorders; therapy using fungicides |
| 05/20/2004 | US20040096518 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 05/20/2004 | US20040096517 Drug obtained from reverse chromatography of human urine; extraction; purification |
| 05/20/2004 | US20040096510 Method of treating androgen- deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 2) a method of preventing androgen- deprivation induced |
| 05/20/2004 | US20040096502 Pharmaceutical pellets comprising tamsulosin |
| 05/20/2004 | US20040096501 Release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form. |
| 05/20/2004 | US20040096500 Reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is |
| 05/20/2004 | US20040096499 A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release |
| 05/20/2004 | US20040096496 Sustained release pharmaceutical composition of a cephalosporin antibiotic |
| 05/20/2004 | US20040096494 Composition in the form of lipoglobules which comprises (a) one or more NO-releasing NSAID(s); (b) one or more surfactants and water as well as a composition for pain and inflamation |
| 05/20/2004 | US20040096493 Preparing a therapeutic formulation containing phosphate derivatives of electron transfer agents comprising steps of phosphorylation and P4O10 to form a mixture of at least one mono-electron transfer agent phosphate derivative and at least |
| 05/20/2004 | US20040096491 Adhesive patch |
| 05/20/2004 | US20040096490 Highly flexible transdermal therapeutic system having nicotine as active substance |
| 05/20/2004 | US20040096487 Treating healed wounds including hypertrophic scars so as to prevent scarring or reduce the size and improve the appearance of scars comprises applying to the healed wound or scar a composition comprising a fluid, film-forming carriers |
| 05/20/2004 | US20040096478 Composition comprising free amino acids |
| 05/20/2004 | US20040096476 Polymeric anti-inflammatory agent that biodegrades to release antiinflammatory agents. The therapeutic devices are useful for repair and regeneration of a variety of injured tissues for wound healing agents |
| 05/20/2004 | US20040096468 An emulsion from about 0.1-70% w/v of a mixture of one or more conjugated diene fatty acids and one or more macromolecules selected from useful as a carrier and delivery vehicle of the macromolecules to humans or animals in need of the |
| 05/20/2004 | US20040096465 Novel receptors for $1(helicobater pyroli) and use thereof |
| 05/20/2004 | US20040096463 Influenza antigen preparation obtainable by the following process, in the manufacture of an intradermal flu vaccine: (i) harvesting of virus-containing material from a culture; (ii) clarification of the harvested material to remove |
| 05/20/2004 | US20040096453 Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described |
| 05/20/2004 | US20040096436 Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a |
| 05/20/2004 | US20040096431 Providing a tissue removal system; removing adipose tissue from a patient using the tissue removal system, the adipose tissue having a concentration of stem cells; processing at least a part of the adipose tissue to obtain a concentration |
| 05/20/2004 | US20040096427 Method of preventing gastro-intestinal dysfunction comprising orally administering a Gram (+) bacteria and glutamine composition. Gram (+) bacteria and glutamine composition for vaccines |
| 05/20/2004 | US20040096425 Method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the |
| 05/20/2004 | US20040096423 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4agonist and a laxative for promoting intestinal lavage |
| 05/20/2004 | US20040096420 Compositions and methods for treating baldness |
| 05/20/2004 | US20040096410 Methods and compositions for treatment of dermal conditions |
| 05/20/2004 | US20040096405 Topical delivery of anti-alopecia agents |
| 05/20/2004 | US20040096403 Method for drug delivery to the pulmonary system |
| 05/20/2004 | US20040096402 Mixing a vapor, formed by heating a compound on a substrate, with a gas, in a ratio to form an aerosol with a mass median aerodynamic diameter of less than 1 mu m when a stable number concentration of particles in the gas is reached. |
| 05/20/2004 | US20040096399 Inhalers containing a solution of an active ingredient in a hydrofluorocarbon propellant and a cosolvent; the internal surfaces consist of stainless steel, anodised aluminium or are lined with an inert organic coating. |
| 05/20/2004 | US20040096393 Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) |
| 05/20/2004 | US20040094749 Having improved solubility and handling properties |
| 05/20/2004 | US20040094449 Melatonin daily dosage units |
| 05/20/2004 | CA2412414A1 Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof |
| 05/19/2004 | EP1420027A2 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds |
| 05/19/2004 | EP1420026A2 Use of conjugates of phytosterol or phytostanol with ascorbic acid in treating or preventing cardiovascular disease, and compositions thereof |
| 05/19/2004 | EP1420023A1 Fused pyrazolyl compounds |
| 05/19/2004 | EP1420022A1 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 05/19/2004 | EP1420020A1 4-oxoimidazolidine-2-spiropiperidine derivative |
| 05/19/2004 | EP1420019A1 Substituted pyridino pentaazamacrocyle ligands having superoxide dismutase activity |
| 05/19/2004 | EP1420018A1 Pyrido[1,2-a]benzimidazole derivatives useful in treating central nervous system disorders |
| 05/19/2004 | EP1420017A1 1,2-dihydro-2-oxo-1,8-naphthyridine derivative |
| 05/19/2004 | EP1420011A1 Compounds usefulfor treating allergic and inflammatory diseases |
| 05/19/2004 | EP1420009A2 Novel amino acid derivatives with improved multi-drug resistance activity |
| 05/19/2004 | EP1419803A2 Pharmaceutical composition for topical administration comprising an antiviral substance and a glucocorticoid |
| 05/19/2004 | EP1419792A1 Glycosaminoglycan-polycation complex crosslinked by polyfunctional crosslinking agent and process for producing the same |
| 05/19/2004 | EP1419780A1 Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of senile dementia and Alzheimer's disease |
| 05/19/2004 | EP1419779A1 Pharmaceutical composition inducing cancer cell differentiation and their use for treatment and prevention of cancer |
| 05/19/2004 | EP1419778A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 05/19/2004 | EP1419777A1 Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors |
| 05/19/2004 | EP1419776A2 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 05/19/2004 | EP1419775A1 Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient |
| 05/19/2004 | EP1419774A1 Pharmaceutical formulations and methods comprising intranasal morphine |
| 05/19/2004 | EP1419773A2 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission |
| 05/19/2004 | EP1419772A1 Preventive agent/remedial agent for constipation predominant ibs |
| 05/19/2004 | EP1419770A1 Apo ai expression accelerating agent |
| 05/19/2004 | EP1419769A1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 05/19/2004 | EP1419768A1 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction |
| 05/19/2004 | EP1419767A1 Remedial agent for cardiac failure |
| 05/19/2004 | EP1419766A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 05/19/2004 | EP1419765A1 Process for manufacturing a solid dosage form comprising an effervescent couple for buccal, gingival or sublingual administration |